These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10832613)

  • 1. [3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors.
    Cussac D; Newman-Tancredi A; Sezgin L; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 2000 May; 361(5):569-72. PubMed ID: 10832613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel antagonist, S33084, and GR218,231 interact selectively with cloned and native, rat dopamine D(3) receptors as compared with native, rat dopamine D(2) receptors.
    Cussac D; Newman-Tancredi A; Sezgin L; Millan MJ
    Eur J Pharmacol; 2000 Apr; 394(1):47-50. PubMed ID: 10771033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The involvement of cerebellar dopamine D3 receptors in locomotor activity of rats.
    Kolasiewicz W; Maj J; Ossowska K
    J Neural Transm (Vienna); 2008 May; 115(5):677-81. PubMed ID: 18188494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [3H](+)S 14297: a novel, selective radioligand at cloned human dopamine D3 receptors.
    Newman-Tancredi A; Audinot V; Jacques V; Peglion JL; Millan MJ
    Neuropharmacology; 1995 Dec; 34(12):1693-6. PubMed ID: 8788967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist.
    Dubuffet T; Newman-Tancredi A; Cussac D; Audinot V; Loutz A; Millan MJ; Lavielle G
    Bioorg Med Chem Lett; 1999 Jul; 9(14):2059-64. PubMed ID: 10450981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
    Pugsley TA; Davis MD; Akunne HC; MacKenzie RG; Shih YH; Damsma G; Wikstrom H; Whetzel SZ; Georgic LM; Cooke LW
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1355-66. PubMed ID: 8531103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
    Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
    J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.
    Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2000 Jun; 293(3):1048-62. PubMed ID: 10869410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signaling pathways leading to phosphorylation of Akt and GSK-3β by activation of cloned human and rat cerebral D₂and D₃ receptors.
    Mannoury la Cour C; Salles MJ; Pasteau V; Millan MJ
    Mol Pharmacol; 2011 Jan; 79(1):91-105. PubMed ID: 20952497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
    Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
    J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study.
    Amenta F; Bronzetti E; Felici L; Ricci A; Tayebati SK
    J Auton Pharmacol; 1999 Jun; 19(3):151-9. PubMed ID: 10511471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinctive binding properties of the negative allosteric modulator, [
    Fasciani I; Pietrantoni I; Rossi M; Mannoury la Cour C; Aloisi G; Marampon F; Scarselli M; Millan MJ; Maggio R
    Eur J Pharmacol; 2018 Jan; 819():181-189. PubMed ID: 29223348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [3H]-quinelorane binds to D2 and D3 dopamine receptors in the rat brain.
    Gackenheimer SL; Schaus JM; Gehlert DR
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1558-65. PubMed ID: 7562534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [3H]nemonapride and [3H]spiperone label equivalent numbers of D2 and D3 dopamine receptors in a range of tissues and under different conditions.
    Vile JM; D'Souza UM; Strange PG
    J Neurochem; 1995 Feb; 64(2):940-3. PubMed ID: 7830089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand.
    Rangel-Barajas C; Malik M; Taylor M; Neve KA; Mach RH; Luedtke RR
    J Neurochem; 2014 Nov; 131(4):418-31. PubMed ID: 25041389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of [3H]nemonapride and [3H]spiperone binding to D2(long) dopamine receptors.
    Vile JM; Strange PG
    Biochem Soc Trans; 1995 Feb; 23(1):90S. PubMed ID: 7538954
    [No Abstract]   [Full Text] [Related]  

  • 19. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
    Sautel F; Griffon N; Sokoloff P; Schwartz JC; Launay C; Simon P; Costentin J; Schoenfelder A; Garrido F; Mann A
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1239-46. PubMed ID: 8531087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors.
    Hidaka K; Tada S; Matsumoto M; Ohmori J; Tasaki Y; Nomura T; Usuda S; Yamaguchi T
    Br J Pharmacol; 1996 Apr; 117(8):1625-32. PubMed ID: 8732269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.